<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37662376</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus infection induces direct pancreatic β-cell killing but poor anti-viral CD8+ T-cell responses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.08.19.553954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.08.19.553954</ELocationID><Abstract><AbstractText>Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β-cell autoimmunity. We investigated how CVB impacts human β cells and anti-CVB T-cell responses. β cells were efficiently infected by CVB <i>in vitro</i>, downregulated HLA Class I and presented few, selected HLA-bound viral peptides. Circulating CD8<sup>+</sup> T cells from CVB-seropositive individuals recognized only a fraction of these peptides, and only another sub-fraction was targeted by effector/memory T cells that expressed the exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with the β-cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Thus, our <i>in-vitro</i> and <i>ex-vivo</i> data highlight limited T-cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8<sup>+</sup> T cells recognizing structural and non-structural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vecchio</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carré</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korenkov</LastName><ForeName>Daniil</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhicheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apaolaza</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research (DZD), Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuomela</LastName><ForeName>Soile</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgos-Morales</LastName><ForeName>Orlando</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snowhite</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Hernandez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandao</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afonso</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliez</LastName><ForeName>Clémentine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaddis</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes and Cancer Discovery Science, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Sally C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>University of Massachusetts Medical Chan School, Diabetes Center of Excellence, Department of Medicine, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Exeter Centre of Excellence for Diabetes Research (EXCEED), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinh</LastName><ForeName>Joelle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ESPCI Paris, PSL University, Spectrométrie de Masse Biologique et Protéomique, CNRS UMR8249, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdier</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>ESPCI Paris, PSL University, Spectrométrie de Masse Biologique et Protéomique, CNRS UMR8249, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laiho</LastName><ForeName>Jutta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tampere University, Faculty of Medicine and Health Technology and Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharfmann</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solimena</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paul Langerhans Institute, Technical University Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinicova</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Paul Langerhans Institute, Technical University Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bismuth</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Assistance Publique Hôpitaux de Paris, Service d'Endocrinologie Pédiatrique, Robert Debré Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucidarme</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Assistance Publique Hôpitaux de Paris, Service de Pédiatrie, Jean Verdier Hospital, Bondy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of pediatric Endocrinology, Leonard Miller School of Medicine, University of Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of pediatric Endocrinology, Leonard Miller School of Medicine, University of Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of pediatric Endocrinology, Leonard Miller School of Medicine, University of Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buus</LastName><ForeName>Soren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Panum Institute, Department of International Health, Immunology and Microbiology, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>nPOD-Virus Working Group</CollectiveName></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Sylvaine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana Biosciences Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyoty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tampere University, Faculty of Medicine and Health Technology and Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Calvo</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research (DZD), Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodstrom-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallone</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana Biosciences Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique Hôpitaux de Paris, Service de Diabétologie et Immunologie Clinique, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK099317</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Sci Adv. 2024 Mar 8;10(10):eadl1122. doi: 10.1126/sciadv.adl1122</RefSource><PMID Version="1">38446892</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">cytotoxic T lymphocytes</Keyword><Keyword MajorTopicYN="N">epitopes</Keyword><Keyword MajorTopicYN="N">glutamic acid decarboxylase</Keyword><Keyword MajorTopicYN="N">immunopeptidome</Keyword><Keyword MajorTopicYN="N">mimicry</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>H.H. is a board member and stock owner in Vactech Ltd, which develops vaccines against picornaviruses and licensed CVB vaccine-related intellectual property rights to Provention Bio Inc. M.F.-T. serves and A.P. served on the scientific advisory board of Provention Bio Inc. R.M. received research funding from Provention Bio Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37662376</ArticleId><ArticleId IdType="pmc">PMC10473604</ArticleId><ArticleId IdType="doi">10.1101/2023.08.19.553954</ArticleId><ArticleId IdType="pii">2023.08.19.553954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carré A., Vecchio F., Flodstrom-Tullberg M., You S., and Mallone R. (2023). Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention. Endocr Rev 44, 737–751. 10.1210/endrev/bnad007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnad007</ArticleId><ArticleId IdType="pubmed">36884282</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie K.M., Bain S.C., Barnett A.H., Bingley P.J., Christie M.R., Gill G.V., and Gale E.A. (2004). The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 364, 1699–1700. 10.1016/S0140-6736(04)17357-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)17357-1</ArticleId><ArticleId IdType="pubmed">15530631</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson C.C., Harjutsalo V., Rosenbauer J., Neu A., Cinek O., Skrivarhaug T., Rami-Merhar B., Soltesz G., Svensson J., Parslow R.C., et al. (2019). Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia 62, 408–417. 10.1007/s00125-018-4763-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4763-3</ArticleId><ArticleId IdType="pubmed">30483858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler A.G., Bonifacio E., and Babydiab-Babydiet Study Group. (2012). Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55, 1937–1943. 10.1007/s00125-012-2472-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2472-x</ArticleId><ArticleId IdType="pubmed">22289814</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikka V., Nanto-Salonen K., Saarinen M., Simell T., Ilonen J., Hyoty H., Veijola R., Knip M., and Simell O. (2012). Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55, 1926–1936. 10.1007/s00125-012-2523-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2523-3</ArticleId><ArticleId IdType="pubmed">22441569</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K., Lynch K.F., Wong M.C., Tian X., Ross M.C., Gibbs R.A., Ajami N.J., Petrosino J.F., Rewers M., Toppari J., et al. (2019). Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med 25, 1865–1872. 10.1038/s41591-019-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua M.P., Alidjinou E.K., and Hober D. (2022). Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 18, 503–516. 10.1038/s41574-022-00688-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-022-00688-1</ArticleId><ArticleId IdType="pmc">PMC9157043</ArticleId><ArticleId IdType="pubmed">35650334</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F., Censini S., van Halteren A.G., Marselli L., Masini M., Dionisi S., Mosca F., Boggi U., Muda A.O., Prato S.D., et al. (2007). Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104, 5115–5120. 10.1073/pnas.0700442104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700442104</ArticleId><ArticleId IdType="pmc">PMC1829272</ArticleId><ArticleId IdType="pubmed">17360338</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L., Edwin B., Buanes T., Frisk G., Skog O., Anagandula M., Korsgren O., Undlien D., Eike M.C., Richardson S.J., et al. (2015). Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64, 1682–1687. 10.2337/db14-1370.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne J.L., Richardson S.J., Atkinson M.A., Craig M.E., Dahl-Jorgensen K., Flodstrom-Tullberg M., Hyoty H., Insel R.A., Lernmark A., Lloyd R.E., et al. (2019). Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 62, 744–753. 10.1007/s00125-019-4811-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-4811-7</ArticleId><ArticleId IdType="pmc">PMC6450860</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Hankaniemi M.M., Laitinen O.H., Sioofy-Khojine A.B., Lin A., Diaz Lozano I.M., Mazur M.A., Marjomaki V., Lore K., Hyoty H., et al. (2020). A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv 6, eaaz2433. 10.1126/sciadv.aaz2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton M.P., Eugster A., Walther D., Daehling N., Riethausen S., Kuehn D., Klingel K., Beyerlein A., Zillmer S., Ziegler A.G., and Bonifacio E. (2016). Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin. Sci Rep 6, 32899. 10.1038/srep32899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32899</ArticleId><ArticleId IdType="pmc">PMC5015062</ArticleId><ArticleId IdType="pubmed">27604323</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft N.P., Smith S.A., Wong Y.C., Tan C.T., Dudek N.L., Flesch I.E.A., Lin L.C.W., Tscharke D.C., and Purcell A.W. (2013). Kinetics of Antigen Expression and Epitope Presentation during Virus Infection. PLOS Pathog 9, e1003129. 10.1371/journal.ppat.1003129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003129</ArticleId><ArticleId IdType="pmc">PMC3561264</ArticleId><ArticleId IdType="pubmed">23382674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachdi L., Maugein A., Pechberty S., Armanet M., Hamroune J., Ravassard P., Marullo S., Albagli O., and Scharfmann R. (2020). Regulated expression and function of the GABA(B) receptor in human pancreatic beta cell line and islets. Sci Rep 10, 13469. 10.1038/s41598-020-69758-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69758-6</ArticleId><ArticleId IdType="pmc">PMC7417582</ArticleId><ArticleId IdType="pubmed">32778664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Duque S., Azoury M.E., Colli M.L., Afonso G., Turatsinze J.V., Nigi L., Lalanne A.I., Sebastiani G., Carre A., Pinto S., et al. (2018). Conventional and Neo-antigenic Peptides Presented by beta Cells Are Targeted by Circulating Naive CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metab 28, 946–960 e946. 10.1016/j.cmet.2018.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.07.007</ArticleId><ArticleId IdType="pubmed">30078552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifie E., Russell M.A., Dhayal S., Leete P., Sebastiani G., Nigi L., Dotta F., Marjomaki V., Eizirik D.L., Morgan N.G., and Richardson S.J. (2018). Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia 61, 2344–2355. 10.1007/s00125-018-4704-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4704-1</ArticleId><ArticleId IdType="pmc">PMC6182664</ArticleId><ArticleId IdType="pubmed">30074059</ArticleId></ArticleIdList></Reference><Reference><Citation>Culina S., Lalanne A.I., Afonso G., Cerosaletti K., Pinto S., Sebastiani G., Kuranda K., Nigi L., Eugster A., Osterbye T., et al. (2018). Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3, eaao4013. 10.1126/sciimmunol.aao4013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aao4013</ArticleId><ArticleId IdType="pmc">PMC5874133</ArticleId><ArticleId IdType="pubmed">29429978</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoury M.E., Tarayrah M., Afonso G., Pais A., Colli M.L., Maillard C., Lavaud C., Alexandre-Heymann L., Gonzalez-Duque S., Verdier Y., et al. (2020). Peptides Derived From Insulin Granule Proteins are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice. Diabetes 69, 2678–2690. 10.2337/db20-0013.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db20-0013</ArticleId><ArticleId IdType="pubmed">32928873</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoury M.E., Samassa F., Buitinga M., Nigi L., Brusco N., Callebaut A., Giraud M., Irla M., Lalanne A.I., Carre A., et al. (2021). CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. Diabetes 70, 2879–2891. 10.2337/db21-0259.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0259</ArticleId><ArticleId IdType="pmc">PMC8660990</ArticleId><ArticleId IdType="pubmed">34561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A.M., Landry L.G., Alkanani A.A., Pyle L., Powers A.C., Atkinson M.A., Mathews C.E., Roep B.O., Michels A.W., and Nakayama M. (2021). Human islet T cells are highly reactive to preproinsulin in type 1 diabetes. Proc Natl Acad Sci USA 118, e2107208118. 10.1073/pnas.2107208118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2107208118</ArticleId><ArticleId IdType="pmc">PMC8521679</ArticleId><ArticleId IdType="pubmed">34611019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann S.E., Zhou Z., Landry L.G., Anderson A.M., Alkanani A.K., Fischer J., Peakman M., Mallone R., Campbell K., Michels A.W., and Nakayama M. (2020). Multiplex T Cell Stimulation Assay Utilizing a T Cell Activation Reporter-Based Detection System. Front Immunol 11, 633. 10.3389/fimmu.2020.00633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00633</ArticleId><ArticleId IdType="pmc">PMC7160884</ArticleId><ArticleId IdType="pubmed">32328071</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., et al. (2008). CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 118, 3390–3402. 10.1172/JCI35449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI35449</ArticleId><ArticleId IdType="pmc">PMC2542849</ArticleId><ArticleId IdType="pubmed">18802479</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Butrym M., Hankaniemi M.M., Sioofy-Khojine A.-B., Hytönen V.P., Hyöty H., and Flodström-Tullberg M. (2021). Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect. Diabetes 70, 2871–2878. 10.2337/db21-0193.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0193</ArticleId><ArticleId IdType="pmc">PMC8660981</ArticleId><ArticleId IdType="pubmed">34497136</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell C.T., Kiosses W.B., Harkins S., and Whitton J.L. (2007). Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J Virol 81, 6785–6797. 10.1128/JVI.00198-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00198-07</ArticleId><ArticleId IdType="pmc">PMC1933326</ArticleId><ArticleId IdType="pubmed">17442717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhn M.H., Hultcrantz M., Lind K., Ljunggren H.G., Malmberg K.J., and Flodstrom-Tullberg M. (2008). IFN-gamma production dominates the early human natural killer cell response to Coxsackievirus infection. Cell Microbiol 10, 426–436. 10.1111/j.1462-5822.2007.01056.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2007.01056.x</ArticleId><ArticleId IdType="pubmed">17961184</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloheimo O., Ihalainen T.O., Tauriainen S., Välilehto O., Kirjavainen S., Niskanen E.A., Laakkonen J.P., Hyöty H., and Vihinen-Ranta M. (2011). Coxsackievirus B3-induced cellular protrusions: structural characteristics and functional competence. J Virol 85, 6714–6724. 10.1128/jvi.00247-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00247-10</ArticleId><ArticleId IdType="pmc">PMC3126532</ArticleId><ArticleId IdType="pubmed">21525342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan S.M., Wherry E.J., and Zajac A.J. (2015). T cell exhaustion during persistent viral infections. Virology 479–480, 180–193. 10.1016/j.virol.2014.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2014.12.033</ArticleId><ArticleId IdType="pmc">PMC4424083</ArticleId><ArticleId IdType="pubmed">25620767</ArticleId></ArticleIdList></Reference><Reference><Citation>McLane L.M., Abdel-Hakeem M.S., and Wherry E.J. (2019). CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37, 457–495. 10.1146/annurev-immunol-041015-055318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055318</ArticleId><ArticleId IdType="pubmed">30676822</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., Ruokoranta T., Lecouturier V., Andre P., Harju R., et al. (2014). Coxsackievirus B1 Is Associated With Induction of beta-Cell Autoimmunity That Portends Type 1 Diabetes. Diabetes 63, 446–455. 10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson M.A., Bowman M.A., Campbell L., Darrow B.L., Kaufman D.L., and Maclaren N.K. (1994). Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 94, 2125–2129. 10.1172/JCI117567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117567</ArticleId><ArticleId IdType="pmc">PMC294659</ArticleId><ArticleId IdType="pubmed">7962558</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloot N.C., Willemen S.J., Duinkerken G., Drijfhout J.W., de Vries R.R., and Roep B.O. (2001). Molecular mimicry in type 1 diabetes mellitus revisited: T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proinsulin peptides do not crossreact with homologous counterpart. Hum Immunol 62, 299–309. 10.1016/s0198-8859(01)00223-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0198-8859(01)00223-3</ArticleId><ArticleId IdType="pubmed">11295462</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela-Calvino R., Skowera A., Arif S., and Peakman M. (2004). Identification of a naturally processed cytotoxic CD8 T-cell epitope of coxsackievirus B4, presented by HLA-A2.1 and located in the PEVKEK region of the P2C nonstructural protein. J Virol 78, 13399–13408. 10.1128/JVI.78.24.13399-13408.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13399-13408.2004</ArticleId><ArticleId IdType="pmc">PMC533958</ArticleId><ArticleId IdType="pubmed">15564450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler A.G., and Bonifacio E. (2020). Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? Diabetologia 63, 1665–1666. 10.1007/s00125-020-05175-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05175-8</ArticleId><ArticleId IdType="pmc">PMC7351841</ArticleId><ArticleId IdType="pubmed">32451571</ArticleId></ArticleIdList></Reference><Reference><Citation>Carré A., Richardson S.J., Larger E., and Mallone R. (2021). Presumption of guilt for T cells in type 1 diabetes: lead culprits or partners in crime depending on age of onset? Diabetologia 64, 15–25. 10.1007/s00125-020-05298-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05298-y</ArticleId><ArticleId IdType="pmc">PMC7717061</ArticleId><ArticleId IdType="pubmed">33084970</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., Roep B.O., and von Herrath M.G. (2012). Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209, 51–60. 10.1084/jem.20111187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111187</ArticleId><ArticleId IdType="pmc">PMC3260877</ArticleId><ArticleId IdType="pubmed">22213807</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana J., Simoni Y., Furio L., Beaudoin L., Agerberth B., Barrat F., and Lehuen A. (2013). Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19, 65–73. 10.1038/nm.3042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3042</ArticleId><ArticleId IdType="pubmed">23242473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemball C.C., Harkins S., Whitmire J.K., Flynn C.T., Feuer R., and Whitton J.L. (2009). Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway. PLoS Pathog 5, e1000618. 10.1371/journal.ppat.1000618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000618</ArticleId><ArticleId IdType="pmc">PMC2757675</ArticleId><ArticleId IdType="pubmed">19834548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.S., Tracy S., Tapprich W., Bailey J., Lee C.K., Kim K., Barry W.H., and Chapman N.M. (2005). 5’-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol 79, 7024–7041. 10.1128/JVI.79.11.7024-7041.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.11.7024-7041.2005</ArticleId><ArticleId IdType="pmc">PMC1112132</ArticleId><ArticleId IdType="pubmed">15890942</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuer R., Mena I., Pagarigan R., Slifka M.K., and Whitton J.L. (2002). Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76, 4430–4440. 10.1128/jvi.76.9.4430-4440.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.9.4430-4440.2002</ArticleId><ArticleId IdType="pmc">PMC155066</ArticleId><ArticleId IdType="pubmed">11932410</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarinen N.V.V., Laiho J.E., Richardson S.J., Zeissler M., Stone V.M., Marjomäki V., Kantoluoto T., Horwitz M.S., Sioofy-Khojine A., and Honkimaa A. (2018). A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses. Sci Rep 8, 1–13. 10.1038/s41598-017-18495-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18495-4</ArticleId><ArticleId IdType="pmc">PMC5758616</ArticleId><ArticleId IdType="pubmed">29311608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard J.S., Ravassard P., Ingvarsen S., Diedisheim M., Bricout-Neveu E., Gronborg M., Frogne T., Scharfmann R., Madsen O.D., Rescan C., and Albagli O. (2016). Xenotropic retrovirus Bxv1 in human pancreatic beta cell lines. J Clin Invest 126, 1109–1113. 10.1172/JCI83573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI83573</ArticleId><ArticleId IdType="pmc">PMC4767346</ArticleId><ArticleId IdType="pubmed">26901817</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinzierl A.O., Rudolf D., Maurer D., Wernet D., Rammensee H.G., Stevanovic S., and Klingel K. (2008). Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. J Gen Virol 89, 2090–2097. 10.1099/vir.0.2008/000711-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/000711-0</ArticleId><ArticleId IdType="pubmed">18753217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Bello I., Cilio C.M., Wong F.S., and Schloot N.C. (2011). Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 163, 33–49. 10.1111/j.1365-2249.2010.04272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2010.04272.x</ArticleId><ArticleId IdType="pmc">PMC3010910</ArticleId><ArticleId IdType="pubmed">20939860</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S., Tauriainen S., Hober D., Lucas B., Vazeou A., Sioofy-Khojine A., Bozas E., Muir P., Honkanen H., Ilonen J., et al. (2014). Virus antibody survey in different European populations indicates risk association between coxsackievirus b1 and type 1 diabetes. Diabetes 63, 655–662. 10.2337/db13-0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0620</ArticleId><ArticleId IdType="pubmed">24009257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead P., Loughrey M.B., Fernandez J.A., Dombrowski Y., McArt D.G., Dunne P.D., McQuaid S., Gray R.T., Murray L.J., Coleman H.G., et al. (2017). QuPath: Open source software for digital pathology image analysis. Sci Rep 7, 16878. 10.1038/s41598-017-17204-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17204-5</ArticleId><ArticleId IdType="pmc">PMC5715110</ArticleId><ArticleId IdType="pubmed">29203879</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigert M., Schmidt U., Haase R., Sugawara K., and Myers G. (2020). Star-convex Polyhedra for 3D Object Detection and Segmentation in Microscopy. Preprint at arXiv, 10.48550/arXiv.1908.03636.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1908.03636</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>